These findings lay the groundwork for further investigation into the timing and context of PBX1, PBX4 and PBXIP1 involvement in leukemogenesis and their response to methyltransferase inhibition, offering a promising approach to halting or reversing leukemic progression in t(7;12) AML. This evidence concerns the gene PBX4 and acute myeloid leukemia.